Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2009 - 2026)

Vanda Pharmaceuticals has disclosed Cash & Current Investments across 18 years of filings, most recently posting $202.3 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $202.3 million, down 40.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.3 million (down 40.66% YoY), and the FY2025 annual result was $263.8 million, down 29.57% from the prior year.
• Cash & Current Investments came in at $202.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $263.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $501.5 million in Q1 2023 to a low of $202.3 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $388.3 million (2023), against an average of $389.7 million.
• Across the five-year window, Cash & Current Investments rose 15.24% in 2023 and tumbled 40.66% in 2026, its largest moves.
• Vanda Pharmaceuticals' Cash & Current Investments stood at $466.9 million in 2022, then fell by 16.83% to $388.3 million in 2023, then retreated by 3.51% to $374.6 million in 2024, then decreased by 29.57% to $263.8 million in 2025, then decreased by 23.32% to $202.3 million in 2026.
• The last three Cash & Current Investments figures came in at $202.3 million (Q1 2026), $263.8 million (Q4 2025), and $293.8 million (Q3 2025), per Business Quant data.